TB 500
Also known as: TB-500, Thymosin beta-4 fragment, Ac-LKKTETQ, Acetyl-LKKTETQ, Thymosin beta-4 fragment (TB-500)
Overview
TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4), a naturally occurring protein found in many human tissues. It is primarily marketed within athletic and bodybuilding communities for its purported benefits in muscle growth, injury recovery, and flexibility improvement. TB-500 consists of a short peptide sequence (Ac-LKKTETQ) and is typically administered via injection. It is important to note that TB-500 is not approved for human use by major regulatory agencies, and its use is considered experimental. Research on TB-500 is primarily preclinical, with limited ex vivo and in vitro studies. Robust clinical trials in humans are lacking, resulting in low to very low quality of evidence regarding its safety and efficacy. While preclinical studies suggest potential for wound healing and tissue regeneration, these effects have not been confirmed in humans.
Benefits
The purported benefits of TB-500 are largely based on preclinical evidence and anecdotal reports, as there are no robust clinical trials confirming its efficacy in humans. Animal studies suggest potential benefits in wound healing, tissue regeneration, and reduced inflammation. However, the effect sizes and clinical significance of these findings are not quantifiable in humans due to the lack of clinical data. Some preclinical studies also suggest potential neuroprotective effects, hair growth promotion, and reduced mortality in sepsis models, but these effects have not been confirmed in human studies. Therefore, no population-specific benefits can be established based on the available evidence. The reported benefits should be interpreted with caution due to the low quality of evidence and lack of regulatory approval.
How it works
TB-500 is a fragment of thymosin beta-4, which plays a role in actin sequestration, cell migration, and tissue repair. It is believed to modulate inflammation, promote angiogenesis (the formation of new blood vessels), and support tissue regeneration. At the molecular level, TB-500 interacts with actin, inflammatory cytokines, and growth factors. Due to its peptide structure, TB-500 is typically administered via injection, as oral bioavailability is likely negligible. In vitro and ex vivo studies indicate that TB-500 undergoes rapid cleavage and metabolism, with the resulting metabolites potentially contributing to the observed effects. However, the precise mechanisms and interactions within the body are not fully understood due to limited research.
Side effects
The safety profile of TB-500 in humans is not well-established due to the lack of robust clinical data. Preclinical studies suggest that thymosin beta-4 is generally safe, but the safety of TB-500, as a specific fragment, cannot be assumed. Common side effects in humans have not been established, but preclinical and anecdotal reports suggest the possibility of injection site reactions. Uncommon and rare side effects are also not established in humans. Drug interactions with TB-500 have not been studied. Due to the lack of data, contraindications are not well-defined, but use during pregnancy, lactation, or in pediatric populations is not recommended. Special populations have not been studied. Given the limited safety data and lack of regulatory oversight, the use of TB-500 carries significant risks, and individuals should exercise extreme caution.
Dosage
There are no established dosage guidelines for TB-500 in humans due to the lack of clinical trials. Anecdotal protocols vary widely, but these are not supported by scientific evidence. The minimum effective dose, optimal dosage ranges, and maximum safe dose have not been determined. Timing considerations for administration are also not established. TB-500 is typically administered via subcutaneous or intramuscular injection, as oral forms are not supported by evidence. Injection is required for systemic delivery, as oral bioavailability is expected to be negligible. No specific cofactors are identified as necessary for TB-500 administration. Given the absence of safety data, it is impossible to define safe upper limits or safety thresholds. Use should be avoided outside of controlled research settings.
FAQs
Is TB-500 approved for human use?
No, TB-500 is not approved for human use by major regulatory agencies. Its use is considered experimental and carries significant risks due to the lack of clinical data and regulatory oversight.
What are the expected results from using TB-500?
There is no reliable evidence to support any specific benefits of TB-500 in humans. Reported effects are based on preclinical or anecdotal data and should be interpreted with caution.
How is TB-500 administered?
TB-500 is typically administered via subcutaneous or intramuscular injection. Oral administration is not effective due to poor bioavailability. However, there are no evidence-based protocols for administration.
Is TB-500 safe?
The safety of TB-500 in humans is unknown. Use is associated with significant risk due to the lack of regulatory oversight and clinical data. Side effects and long-term consequences are not well-understood.
What is TB-500?
TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring protein. It is marketed for potential benefits in muscle growth and injury recovery, but lacks clinical validation.
Research Sources
- https://www.wada-ama.org/en/resources/scientific-research/investigation-vitroex-vivo-tb-500-metabolism-synthesis-relevant – This in vitro/ex vivo study investigated the metabolism of TB-500 and synthesized relevant metabolites. The key finding was that TB-500 undergoes rapid cleavage at the C-terminus, and acetylation of leucine provides protection, suggesting that metabolites may contribute to its biological activity. This study provides mechanistic insight but has limited clinical relevance due to the absence of human data.
- https://www.innerbody.com/thymosin-beta-4-and-tb-500 – This narrative review summarizes preclinical and clinical literature on TB-500 and thymosin beta-4. It highlights that TB-500 (Ac-LKKTETQ) did not increase wound healing activity in one study, but its metabolite (Ac-LKKTE) did, and emphasizes the lack of human safety or efficacy data for TB-500. While providing a summary of available evidence, it is not a systematic review and relies heavily on preclinical data, limiting its clinical recommendation value.
- https://pubmed.ncbi.nlm.nih.gov/32293681/ – This case series analysis of supplement labels highlights concerns about the accuracy and safety of novel supplement ingredients, including peptides like TB-500. It emphasizes that these substances are not well-regulated or studied, raising concerns about their potential risks. While it does not directly study TB-500, it provides valuable insight into the regulatory landscape surrounding such supplements.
- https://www.orthoandwellness.com/blog/tb-500-exposed-the-risks-outweigh-the-benefits – This article discusses the risks associated with TB-500, highlighting the lack of clinical evidence supporting its benefits and the potential for adverse effects. It emphasizes that the risks of using TB-500 outweigh any potential benefits due to the absence of human safety and efficacy data. The article serves as a cautionary resource against the use of TB-500 outside of controlled research settings.
- https://www.mcgill.ca/oss/article/critical-thinking-health-and-nutrition/human-lab-rats-injecting-themselves-peptides – This article discusses the trend of individuals using peptides like TB-500 for performance enhancement, highlighting the lack of regulation and scientific evidence supporting their use. It raises concerns about the potential risks and unknown long-term effects of injecting oneself with these substances. The article serves as a critical perspective on the use of peptides outside of clinical trials.
